Takeda, Evox link up to the tune of $882m
Evox will offer its preclinical programme in Niemann-Pick disease type C for development, and a second new programme directed at another undisclosed rare disease.
Read More
Tag: Niemann-Pick disease type C
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
